Lung cancer culprit could offer
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Twitter ~ Facebook
Home / Technology News / 2010 / September 2010 / September 14, 2010
Lung cancer culprit could offer therapeutic target
RSS / Print / Comments

Lung Cancer

TTF therapy, chemo combo 'increase survival for lung cancer patients'

Surveys Highlight Advancing Confidence in Erbitux as Only Targeted Treatment to Increase Survival and Potential for Cure in Head and Neck Cancer

More on Lung Cancer

Technology News

Study to find whether leptin helps type 1 diabetic patients
To determine whether adding the hormone leptin to standard insulin therapy might help rein in the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes, a clinical trial at UT Southwestern Medical Center is being carried out. ANI

Why deaf have 'super vision'
Researchers have found reasons for the enhanced abilities in the remaining senses of deaf people. ANI

Tsunami risk higher than expected in LA, other major cities
A new study has revealed that the risk of destructive tsunamis is in places such as Kingston, Istanbul, and Los Angeles. ANI

Lung cancer culprit could offer therapeutic target

New research has suggested that a tiny molecule, which spurs the progression of lung cancer, could become a key player in fighting the disease.


Washington, Sep 14 : New research has suggested that a tiny molecule, which spurs the progression of lung cancer, could become a key player in fighting the disease.

Scientists have known that the molecule microRNA-21, or miR-21, is present in overabundant quantities in human tumors, including non-small-cell lung cancer (NSCLC).

Until now, however, it was unclear whether miR-21 contributed to the development of lung cancer, or whether it was simply an indicator of the presence of the disease.

To find out, lead study author Dr. Mark Hatley, an instructor of pediatric hematology/oncology, and UT Southwestern colleagues used mice that had been altered specifically to harbor non-small-cell lung cancer.

In some of these mice, they genetically engineered the animals to produce too much miR-21. In another group, they deleted the miR-21 gene altogether, which eliminated the molecule in the rodents.

In animals with cancer, the results showed that too much miR-21, or overexpression, promotes the formation, growth and survival of new tumors by turning off certain genes that normally allow cancer cells to die.

In fact, at 18 weeks of age, the study group with overexpressed miR-21 had significantly more tumors than their lung-cancer-carrying littermates with normal levels of miR-21. Healthy rodents engineered to overexpress miR-21 did not develop cancer.

"These results indicate that overexpression of miR-21 alone is not enough to initiate tumors in a healthy animal. Instead, it appears that miR-21 enhances the growth and survival of existing lung cancer," said Dr. Hatley, a Pediatric Scientist Development Program fellow.

Dr. Eric Olson, chairman of molecular biology at UT Southwestern and the study's senior author, said the experiments also show that deleting miR-21 sensitizes the animals' cancer cells to a certain kind of chemotherapy, suggesting that inhibiting miR-21 in lung-cancer patients could be of therapeutic value.

"More research will be needed before we know whether this is applicable to humans, but it's possible that a drug designed to inhibit miR-21 could help keep cancer at bay," he added.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us